Search

Your search keyword '"Harada, Noriko"' showing total 43 results
Start Over Author "Harada, Noriko"
43 results on '"Harada, Noriko"'

7. Polymers in Therapeutic Delivery

Author

Tomoko Fujiwara, X. Michael Liu, Yuichi Ohya, Yongmei Wang, Caleb Gallops, Jesse Ziebarth, Yongmei Wang, Ryuta Aono, Kenta Nomura, Eiji Yuba, Atsushi Harada, Noriko Miyamoto, Shinichi Mochizuki, Nobuaki Fujiwara, Hiroto Izumi, Kazuo Sakurai, Yuta Yoshizaki, Hiroki Yamamoto, Akinori Kuzuya, Yuichi Oh

Published
2020

11. S-04-4: INCONSISTENT GUIDELINES-BASED CONTROL STATUS OF OFFICE, HOME, AND AMBULATORY BLOOD PRESSURE MEASURED BY AN ALL-IN-ONE BP MONITORING DEVICE

Author

Kario, Kazuomi, primary, Hoshide, Satoshi, additional, Tomitani, Naoko, additional, Nishizawa, Masafumi, additional, Yoshida, Tetsuro, additional, Kabutoya, Tomoyuki, additional, Fujiwara, Takeshi, additional, Mizuno, Hiroyuki, additional, Narita, Keisuke, additional, Komori, Takahiro, additional, Suzuki, Daisuke, additional, Nakazato, Jun, additional, Nakagawa, Naoki, additional, Katsuya, Tomohiro, additional, and Harada, Noriko, additional

Published
2023
Full Text
View/download PDF

14. Inconsistent Control Status of Office, Home, and Ambulatory Blood Pressure All Taken Using the Same Device: The HI–JAMP Study Baseline Data

Author

Kario, Kazuomi, primary, Hoshide, Satoshi, additional, Tomitani, Naoko, additional, Nishizawa, Masafumi, additional, Yoshida, Tetsuro, additional, Kabutoya, Tomoyuki, additional, Fujiwara, Takeshi, additional, Mizuno, Hiroyuki, additional, Narita, Keisuke, additional, Komori, Takahiro, additional, Ogata, Yukiyo, additional, Suzuki, Daisuke, additional, Ogoyama, Yukako, additional, Ono, Akifumi, additional, Yamagiwa, Kayo, additional, Abe, Yasuhisa, additional, Nakazato, Jun, additional, Nakagawa, Naoki, additional, Katsuya, Tomohiro, additional, Harada, Noriko, additional, and Kanegae, Hiroshi, additional

Published
2022
Full Text
View/download PDF

21. Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study

Author

Kario, Kazuomi, primary, Okada, Kenta, additional, Murata, Mitsunobu, additional, Suzuki, Daisuke, additional, Yamagiwa, Kayo, additional, Abe, Yasuhisa, additional, Usui, Isao, additional, Tsuchiya, Norihiro, additional, Iwashita, Chie, additional, Harada, Noriko, additional, Okawara, Yukie, additional, Ishibashi, Shun, additional, and Hoshide, Satoshi, additional

Published
2020
Full Text
View/download PDF

22. Patterns of drug treatment in patients with osteoarthritis and chronic low back pain in Japan: a retrospective database study

Author

Akazawa, Manabu, Mimura, Wataru, Togo, Kanae, Ebata, Nozomi, Harada, Noriko, Murano, Haruka, Abraham, Lucy, and Fujii, Koichi

Subjects
osteoarthritis, chronic low back pain, opioid, non-steroidal anti-inflammatory drugs, pain, Journal of Pain Research, human activities, humanities, Original Research
Abstract

Manabu Akazawa,1 Wataru Mimura,1 Kanae Togo,2 Nozomi Ebata,3 Noriko Harada,4 Haruka Murano,5 Lucy Abraham,6 Koichi Fujii31Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan; 2Corporate Affairs, Health & Value, Pfizer Japan Inc., Tokyo, Japan; 3Medical Affairs, Pfizer Japan Inc., Tokyo, Japan; 4Clinical Research, Pfizer R&D Japan G.K., Tokyo, Japan; 5Clinical Research Professionals, Clinical Study Support Inc., Nagoya, Japan; 6Patient & Health Impact, Pfizer Ltd., Surrey, UKPurpose: Musculoskeletal diseases, including osteoarthritis (OA) and low back pain (LBP), are the leading causes of years lived with disability, and are associated with lowered quality-of-life, lost productivity, and increased healthcare costs. However, information publicly available regarding the Japanese real-world usage of prescription medications is limited. This study aimed to describe the clinical characteristics of patients with OA and chronic LBP (CLBP), and to investigate the patterns of medications and opioid use in Japanese real-world settings.Materials and methods: A retrospective study was conducted using a Japanese administrative claims database between 2013 and 2017. The outcomes were patient characteristics and prescription medications, and they were evaluated separately for OA and CLBP.Results: The mean age of 118,996 patients with OA and 256,402 patients with CLBP was 68.8±13.1 years and 64.8±16.4 years, respectively. Approximately 90% of patients with OA and CLBP were prescribed non-steroidal anti-inflammatory drugs (NSAIDs). Other prescriptions included hyaluronate injection (35.6%), acetaminophen (21.4%), and steroid injection (20.0%) in patients with OA, and pregabalin (39.0%) and acetaminophen (22.4%) in patients with CLBP. Weak opioids were prescribed to 10.7% and 20.6% of patients with OA and CLBP, respectively. The prescription of COX-2 inhibitors (OA: +6.5%; CLBP: +6.7%) and acetaminophen (OA: +16.4%; CLBP: +14.4%) increased between 2013 and 2017. The first commonly prescribed medication among patients with OA and CLBP were NSAIDs; hyaluronate injection (patients with OA) and pregabalin (patients with CLBP) were also common first-line medications. Acetaminophen, steroid injection (patients with OA), and weak opioids were prescribed more in the later phases of treatment.Conclusion: Most patients were prescribed limited classes of pain drugs, with NSAIDs being the most common pain medication in Japan for patients with OA and CLBP. Opioid prescription was uncommon, and were weak opioids when prescribed.Keywords: osteoarthritis, chronic low back pain, non-steroidal anti-inflammatory drugs, opioid, pain

Published
2019

24. Patterns of drug treatment in patients with osteoarthritis and chronic low back pain in Japan: a retrospective database study

Author

Akazawa,Manabu, Mimura,Wataru, Togo,Kanae, Ebata,Nozomi, Harada,Noriko, Murano,Haruka, Abraham,Lucy, Fujii,Koichi, Akazawa,Manabu, Mimura,Wataru, Togo,Kanae, Ebata,Nozomi, Harada,Noriko, Murano,Haruka, Abraham,Lucy, and Fujii,Koichi

Abstract

Manabu Akazawa,1 Wataru Mimura,1 Kanae Togo,2 Nozomi Ebata,3 Noriko Harada,4 Haruka Murano,5 Lucy Abraham,6 Koichi Fujii31Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan; 2Corporate Affairs, Health & Value, Pfizer Japan Inc., Tokyo, Japan; 3Medical Affairs, Pfizer Japan Inc., Tokyo, Japan; 4Clinical Research, Pfizer R&D Japan G.K., Tokyo, Japan; 5Clinical Research Professionals, Clinical Study Support Inc., Nagoya, Japan; 6Patient & Health Impact, Pfizer Ltd., Surrey, UKPurpose: Musculoskeletal diseases, including osteoarthritis (OA) and low back pain (LBP), are the leading causes of years lived with disability, and are associated with lowered quality-of-life, lost productivity, and increased healthcare costs. However, information publicly available regarding the Japanese real-world usage of prescription medications is limited. This study aimed to describe the clinical characteristics of patients with OA and chronic LBP (CLBP), and to investigate the patterns of medications and opioid use in Japanese real-world settings.Materials and methods: A retrospective study was conducted using a Japanese administrative claims database between 2013 and 2017. The outcomes were patient characteristics and prescription medications, and they were evaluated separately for OA and CLBP.Results: The mean age of 118,996 patients with OA and 256,402 patients with CLBP was 68.8±13.1 years and 64.8±16.4 years, respectively. Approximately 90% of patients with OA and CLBP were prescribed non-steroidal anti-inflammatory drugs (NSAIDs). Other prescriptions included hyaluronate injection (35.6%), acetaminophen (21.4%), and steroid injection (20.0%) in patients with OA, and pregabalin (39.0%) and acetaminophen (22.4%) in patients with CLBP. Weak opioids were prescribed to 10.7% and 20.6% of patients with OA and CLBP, respectively. The prescription of COX-2 inhibitors (OA: +6.5%; CLBP: +6.7%) and acetaminophen (OA: +16.4

Published
2019

31. A Study on Anxiety of Skate Beginners

Author

Nunome, Yasunori, Tazaki, Kentaro, KAWAI, Toshinobu, Takano, Satoshi, Yorikane, Yoshinori, Sakata, Isao, YAMADA, Yukio, SAGA, Hitoshi, Saito, Taketoshi, Minami, Takahisa, Tsukahara, Masao, Harada, Noriko, and Nakajima, Setsuko

Published
1995

37. Antibiotic Susceptibility Patterns as Aids in Classification and Characterization of Gram-negative Anaerobic Bacilli

Author

Finegold, Sydney M., Harada, Noriko E., and Miller, Lawrence G.

Abstract

Patterns of susceptibility of gram-negative anaerobic bacilli to antibiotics have been found to be distinctive and of significant help in classification and identification. Five major groups of gram-negative anaerobic bacilli have been defined on the basis of morphological and biochemical criteria. Antibiotic sensitivity patterns conform to these groupings and provide additional taxonomic criteria. The Bacteroides fragilisgroup is resistant to penicillin G, whereas the other groups are generally sensitive. B. fragilisstrains are relatively sensitive to erythromycin, whereas the Sphaerophorus necrophorusgroup is resistant. B. melaninogenicusstrains, B. oralis, and Fusobacteriumare all more sensitive to kanamycin and neomycin than the other two groups. Kanamycin is more active against Fusobacteriumstrains than neomycin, but less active against all other groups. Colistin or polymyxin B is useful for distinguishing between the resistant B. fragilisand the sensitive S. necrophorus. Antibiotic susceptibility determinations may be more readily performed in clinical laboratories than certain biochemical tests recommended for differentiation of the gram-negative anaerobic bacilli and may serve as helpful adjuncts to morphological and biochemical observations in classifying and characterizing these organisms. The use of standardized procedures for antibiotic susceptibility tests is essential if comparable results are to be obtained in different laboratories.

Published
1967
Full Text
View/download PDF

43. Inconsistent Control Status of Office, Home, and Ambulatory Blood Pressure All Taken Using the Same Device: The HI-JAMP Study Baseline Data.

Author

Kario K, Hoshide S, Tomitani N, Nishizawa M, Yoshida T, Kabutoya T, Fujiwara T, Mizuno H, Narita K, Komori T, Ogata Y, Suzuki D, Ogoyama Y, Ono A, Yamagiwa K, Abe Y, Nakazato J, Nakagawa N, Katsuya T, Harada N, and Kanegae H

Subjects
Humans, Blood Pressure, Blood Pressure Monitoring, Ambulatory methods, Blood Pressure Determination methods, Hypertension diagnosis, Hypertension drug therapy, White Coat Hypertension diagnosis
Abstract

Background: Inconsistencies between the office and out-of-office blood pressure (BP) values (described as white-coat hypertension or masked hypertension) may be attributable in part to differences in the BP monitoring devices used., Methods: We studied consistency in the classification of BP control (well-controlled BP vs. uncontrolled BP) among office, home, and ambulatory BPs by using a validated "all-in-one" BP monitoring device. In the nationwide, general practitioner-based multicenter HI-JAMP study, 2,322 hypertensive patients treated with antihypertensive drugs underwent office BP measurements and 24-hour ambulatory BP monitoring (ABPM), consecutively followed by 5-day home BP monitoring (HBPM), for a total of seven BP measurement days., Results: Using the thresholds of the JSH2019 and ESC2018 guidelines, the patients with consistent classification of well-controlled status in the office (<140 mmHg) and home systolic BP (SBP) (<135 mmHg) (n = 970) also tended to have well-controlled 24-hour SBP (<130 mmHg) (n = 808, 83.3%). The patients with the consistent classification of uncontrolled status in office and home SBP (n = 579) also tended to have uncontrolled 24-hour SBP (n = 444, 80.9%). Among the patients with inconsistent classifications of office and home BP control (n = 803), 46.1% had inconsistent ABPM-vs.-HBPM out-of-office BP control status. When the 2017 ACC/AHA thresholds were applied as an alternative, the results were essentially the same., Conclusions: The combined assessment of the office and home BP is useful in clinical practice. Especially for patients whose office BP classification and home BP classification conflict, the complementary clinical use of both HBPM and ABPM might be recommended., (© The Author(s) 2022. Published by Oxford University Press on behalf of American Journal of Hypertension, Ltd. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results